Lyondellbasell Builds Pilot Chemical Recycling Plant

LyondellBasell builds pilot chemical recycling plantEUWID | October 17, 2019
Plastics producer LyondellBasell will build a small-scale pilot "molecular recycling" plant in Ferrara, Italy in order to move towards converting difficult to recycle post-consumer plastic waste into new plastic. The facility is to help the company advance the "MoReTec" recycling technology towards commercial scale, according to Jim Seward, LyondellBasell Senior Vice President of Research & Development, Technology and Sustainability. LyondellBasell has developed the recycling technology jointly with the Karlsruhe Institute for Technology (KIT). The process is based on pyrolysis but includes a "proprietary catalyst-based approach"."We have advanced our chemical recycling capabilities over the last 15 months, and through research and testing we are studying a number of LyondellBasell proprietary catalyst options," said Mr Seward. The MoReTec technology has the goal to convert typically difficult to recycle plastic waste such as multi-layer films, returning them to their molecular state to be used as feedstock to produce new plastic for all applications including food contact and healthcare items, according to LyondellBasell.
Chemify and Prepaire Labs announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire's integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA's Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform.Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products.Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis."We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication. With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need," said Professor Lee Cronin, Chemify's Founder and CEO."Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators. There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder," said Dr Vicent Ribas, Prepaire's Co-Founder.About ChemputationDigital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible. Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety.About ChemifyBased in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.About Prepaire LabsPrepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE.
Pall Corporation, a leading provider of filtration, separation and purification solutions, introduces SepraLYTE liquid/gas coalescers, an innovative solution designed to meet the increasing demand for efficient separation of electrolyte aerosols from gas in green hydrogen production processes.Leveraging advanced separation technology, SepraLYTE coalescers excel in the separation of water or electrolyte aerosols (30% potassium hydroxide solution) from hydrogen, ensuring the purity of hydrogen produced from electrolysis processes. They are highly suitable for a wide range of separation applications where minimal pressure drop is crucial for downstream processes."Our new SepraLYTE coalescers represent Pall's commitment to serving our customers in energy transition markets. Pall continues to innovate to address new and challenging customer needs in fast growing markets like green hydrogen," said Greg Sears, Vice President and General Manager of Pall's Fluid Technologies and Asset Protection business unit."Pall's coalescers enable our customers to optimize their plant design, maximize the lifetime of their critical equipment and improve overall efficiency, reliability and output," said Sears.These coalescers feature Pall's proprietary melt blown media technology, which achieves outstanding liquid mist separation with low differential pressure. The compact design incorporates coalescer media that ensures compatibility with various chemical applications. Other key advantages of SepraLYTE liquid/gas coalescers is the ease of maintenance, compact size and waste reduction.Utilizing SepraLYTE liquid/gas coalescers, customers gain significant advantages over conventional separation products. These advantages include reliable, consistent and verifiable separation performance, high gas flow and liquid removal in a compact cartridge, which allow for smaller systems with low capital, operating, and maintenance costs.About Pall CorporationPall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of industries. Pall collaborates with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste.
Headquartered in Luxembourg, ChemChain's proprietary IP and technology will bring an expanded, innovative approach to further augment 3E's Supply Chain & Sustainability solution, 3E Exchange. 3E Exchange's unified supply chain platform helps customers organize their global library of supply chain data and streamline workflows in a scalable and compliant manner. Specifically, 3E leverages its market leading digital product passport and renowned regulatory content capabilities to drive best-in-class supply chain management for its growing list of customers. Together, 3E and ChemChain are united in their mission to accelerate global supply chain transparency and sustainability with a unique combination of technology and regulatory expertise."ChemChain and 3E share a vision to create a safer, more sustainable world that protects people, safeguards products, and helps businesses grow," said Greg Gartland, Chief Executive Officer of 3E. "Together with ChemChain, 3E offers an unmatched combination of global regulatory expertise and a cutting-edge platform that dramatically simplifies transferring information along the value chain in a transparent and secure manner. 3E improves cross-functional engagement across global enterprises, and future-proofs products against ever-changing regulations. We look forward to the continued expansion of our supply chain solutions and empowering our clients to further accelerate their sustainability efforts."With 175,000+ supplier relationships across all major geographies, the 3E Exchange platform drives a strong return-on-investment for its customers. Powered by 3E's market leading regulatory expertise covering over 500,000 chemical substances, 3E Exchange enables superior supply chain management while also advancing companies' ESG objectives. Continued momentum towards sustainable supply chains has highlighted that preparing for a circular economy should be a critical component of every company's product strategy.Pete Girard, Managing Director of Supply Chain and Sustainability at 3E, said "The acquisition of ChemChain illustrates our continued focus on supply chain product innovation and thought leadership. The ChemChain team has incubated a novel and tech-forward approach to drive digital product passport adoption, and we look forward to integrating these technologies into 3E Exchange.""The highly scalable digital product passport model offers a single source of truth that underpins sustainable supply chain management, while ensuring maximum protection of company trade secrets" added Lorenzo Zullo, Co-Founder and CEO of ChemChain. "As part of 3E, and leveraging tracked experience in end-to-end supply chain transparency across multiple industries, including textile & clothing, furniture, and detergents, ChemChain will accelerate innovation and position customers for success in the face of a highly complex and dynamic global regulatory landscape."ChemChain represents 3E's fourth acquisition announcement since its separation from Verisk in March 2022.Shearman & Sterling LLP served as the legal advisor to 3E. Cambrian and Elev8law served as the legal advisors to ChemChain.About 3EFor more than 35 years the world's leading companies have trusted 3E to provide the intelligent compliance solutions they need to ensure safety and sustainability. Unmatched Environmental, Health, Safety and Sustainability (EHS&S) and product compliance expertise empowers clients to improve chemical and workplace safety, product safety and stewardship and supply chain transparency. 3E is deeply committed to serving its more than 5,000 customers worldwide, representing a wide variety of industries and including the world's largest chemical manufacturers, retailers and pharmaceutical companies.About ChemChainChemChain is a trusted, decentralized, and globally accepted infrastructure that enables customers to build, exchange, store, and track chemical-related information along the supply chain. ChemChain's proprietary architecture, underpinned by blockchain technology, facilitates a scalable and tamper-proof digital product passport environment.
#J-18808-Ljbffr